This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

Beta-Blockers Exert Anti-Atherosclerotic Effects

Posted: Saturday, July 14, 2007

Beta-blocker therapy can provide statistically significant regression of coronary artery plaque, and slow the progression to coronary atherosclerosis.

Lipid Effects of Diabetes Agents May Protect Arterial Function

Posted: Saturday, July 14, 2007

Lipoprotein subfraction changes may be at the root of the dyslipidemia accompanying type 2 diabetes and help explain how thiazolidinediones improve carotid intima-media thickness.

U.S. Survey Shows Uninsured Numbers 43.6 Million

Posted: Saturday, July 07, 2007

Just under 44 million Americans had no health insurance in 2006, according to a survey by the U.S. Centers for Disease Control and Prevention.

Rosiglitazone Debated at ADA Meeting

Posted: Saturday, July 07, 2007

They were waiting in a long line outside the hall to see Dr Steven Nissen (Cleveland Clinic, OH). He arrived to a packed auditorium to tell the audience what he knew about rosiglitazone (Avandia, GlaxoSmithKline), when he knew it, and what he believes needs to be done next.

New Class of Diabetes Drugs Effective in Controlling Blood Glucose

Posted: Saturday, June 30, 2007

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes.

Statins and Fibrates Prevents Diabetic Neuropathy by 48%

Posted: Saturday, June 30, 2007

A major epidemiological study conducted over eight years in Australia has shown that two classes of lipid-lowering drugs - statins and fibrates - significantly lower the risk of developing nerve damage known as peripheral sensory diabetic neuropathy.

New Drug Cycloset Improves Glucose Control and Reduces CVD Risk

Posted: Saturday, June 30, 2007

A quick release formulation of bromocriptine mesylate in patients with type 2 diabetes improves glycemic control and reduces diabetic cardiovascular complications.

Diabetes a Risk Factor for Cardiovascular Morbidity and Mortality in 3.3 Million Subjects

Posted: Saturday, June 30, 2007

A new study concludes that patients with type 2 diabetes 30 years of age and older who are receiving glucose-reducing treatment should also receive prompt intensive prophylactic treatment for cardiovascular disease.

Patients Beat Physicians at Insulin Dose Adjustment

Posted: Saturday, June 30, 2007

Type 2 diabetes patients taught to titrate their own insulin detemir (Levemir) dose may equal or exceed the results that physicians achieve, researchers reported.

Risk of Subsequent Hypoglycemia is Low When Diabetes Treatment is Intensified

Posted: Saturday, June 30, 2007

Clinicians should not be afraid of intensifying treatment in diabetic patients with inadequately controlled glucose levels because the subsequent risk of developing hypoglycemia is quite low, a new study has shown.